Clinical Trials Logo

Filter by:
NCT ID: NCT06463834 Recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma

Start date: March 20, 2024
Phase: Phase 2
Study type: Interventional

This study is aimed to evaluate the efficacy and safety of sintilimab combined with chemotherapy (docetaxel+cisplatin+5-fluorouracil, DCF) in neoadjuvant treatment of locally advanced esophageal squamous cell carcinoma.

NCT ID: NCT06463808 Recruiting - Clinical trials for Ventricular Remodeling

Effect of Recombinant Human Brain Natriuretic Peptide on Ventricular Remodeling and Cardiac Function in Patients With Acute Anterior Myocardial Infraction Undergoing Percutaneous Coronary Intervention

Start date: May 3, 2023
Phase:
Study type: Observational

This study is designed to evaluate the efficacy and safety of Recombinant Human Brain Natriuretic Peptide (rhBNP) in improving ventricular remodeling and cardiac function after acute anterior myocardial infarction undergoing percutaneous coronary intervention. 100 patients with acute anterior myocardial infarction after primary Percutaneous Coronary Intervention (pPCI) are randomly assigned 1:1 to rhBNP group(n=50) and control group(n=50) with follow-up of 24 weeks. Both groups are treated with standard therapy of AAMI, with the rhBNP group intravenous dripping rhBNP after pPCI for 3 days and the control group treated with placebo at the same time. The primary endpoint is the change in N terminal pro-B-type natriuretic peptide(NT-proBNP )and cardiac troponin T(cTnT) level.The secondary endpoint is the change in 24-week echocardiographic including left ventricle ejection fraction (LVEF) , left ventricular end-diastolic volume index (LVEDVI) and left ventricular end-systolic volume index (LVESVI), arrhythmia and cardiovascular events (death, cardiac arrest or cardiopulmonary resuscitation, hospitalization due to heart failure or angina pectoris).

NCT ID: NCT06463756 Recruiting - Laryngeal Carcinoma Clinical Trials

CT-based Radiomics and Deep Learning Models to Predict Thyroid Cartilage Invasion and Patient Prognosis in Laryngeal Carcinoma

Start date: August 13, 2023
Phase:
Study type: Observational

This retrospective study was to develop and verify a CT-based radiomics model, 2D deep learning model and 3D deep learning model to preoperatively predict the thyroid cartilage invasion of laryngeal cancer patients, so as to provide more accurate diagnosis and treatment basis for clinicians. And the performance of the aforementioned models was compared with two radiologists. In addition, the researchers investigated the prediction of survival outcomes of patients by the above optimal models.

NCT ID: NCT06463717 Recruiting - Multiple Myeloma Clinical Trials

Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not

Start date: December 1, 2023
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to compare the efficacy and safety of autologous hematopoietic stem-cell transplantation (ASCT) versus non ASCT regimens in primary multiple myeloma patients achieved MRD negativity after induction. The main question it aims to answer is: In primary multiple myeloma patients who achieved MRD negativity after induction, non ASCT regimens are not inferior to ASCT or not? Participants will receive ASCT or non ASCT regimen according to their own choice. Researchers will compare ASCT and non ASCT group see if any significant difference in efficacy and safety.

NCT ID: NCT06463444 Recruiting - HCC Clinical Trials

Precision Treatment of Unresectable HCC Guided by Multi-omics Deep Learning Models

Start date: June 1, 2024
Phase: Phase 1
Study type: Interventional

Surgery is the main curative treatment for hepatocellular carcinoma(HCC) patients, but 70%-80% of HCC patients are in the middle and advanced stages at the time of diagnosis and cannot be surgically resected. Local and systemic therapy are the main treatments for unresectable HCC. Two recent trials of HAIC combined with PD-1 monoclonal antibody and targeted therapy reported objective response rates (ORR) as high as 43.3% to 77.1%.

NCT ID: NCT06463366 Recruiting - Liver Stiffness Clinical Trials

Multifrequency MRE for Assessing Chronic Hepatic Disease

Start date: July 1, 2024
Phase:
Study type: Observational

To construct a novel, non-invasive, accurate, and convenient method to achieve the degree of liver damage is an important general problem in the management of patients with chronic liver disease. The investigators would like to develop non invasive advanced Magnetic Resonance Imaging (MRI) techniques (MR elastography, MRI-PDFF) to assess the degree of liver damage in patients with chronic liver disease. These techniques could reach high diagnostic performance for detection of liver fibrosis, inflammation and liver fat content; and could decrease the number of liver biopsies, which have risks and sample only a small portion of the liver.

NCT ID: NCT06463236 Recruiting - Clinical trials for Anemia of Chronic Kidney Disease

Clinical Validation of the Management Process for Renal Anemia in Maintenance Hemodialysis Patients

Start date: June 14, 2024
Phase: N/A
Study type: Interventional

This test aims to verify that the management process of renal anemia in maintenance hemodialysis patients can improve the hemoglobin compliance rate better than that of anemia management by primary doctors, and promote the system at the grassroots level to guide primary doctors in anemia management and improve the management standard of renal anemia in maintenance hemodialysis patients through prospective randomized controlled trials. To improve the anemia compliance rate of maintenance hemodialysis patients, and to improve the basic doctors' grasp of the anemia management guidelines, consensus and standard operating procedures.

NCT ID: NCT06462742 Recruiting - Overall Survival Clinical Trials

Microwave Ablation Versus Liver Resection for Intrahepatic Cholangiocarcinoma

MALRIC
Start date: January 1, 2009
Phase:
Study type: Observational

Thermal ablation has been recommended by worldwide guidelines as first-line treatment for hepatocellular carcinoma (HCC), while evidence regarding its efficacy for primary intrahepatic cholangiocarcinoma (iCCA) is lacking. The goal of this observational study is to study the efficacy of ablation in treating iCCA by comparing its prognosis with surgery. The main questions it aims to answer are: - Whether microwave ablation could achieve similar efficacy with liver resection in treating iCCA - What is the risk factor for ablation or surgery in treating iCCA - What kind of iCCA patients could receive ablation as their first-line treatment In this real-world multicenter cohort study, we will collect data of iCCA patients from hospitals who underwent microwave ablation (MWA) or liver resection (LR) for tumors within Milan criteria. Survival will be compared between patients treated by MWA or LR.

NCT ID: NCT06462716 Recruiting - Solid Tumor, Adult Clinical Trials

A Phase l Study of By101298, an Oral DNA-PK Inhibitor, in Patients With Advanced Solid Tumors

Start date: April 25, 2023
Phase: Phase 1
Study type: Interventional

BY101298 is an innovative DNA-dependent protein kinases (DNA-PK) highly selective small molecule inhibitor. DNA-dependent protein kinases (DNA-PK plays a key role in the NHEJ repair pathway to repair DNA double-strand breaks (DSBs). Primary objective is to assess the safety and tolerability of BY101298 in patients with advanced malignant solid tumors. The secondary Objectives are to characterize the pharmacokinetic (PK) profile of BY101298 in patients with advanced malignant solid tumors and to assess the preliminary efficacy of BY101298 in patients with advanced malignant solid tumors.

NCT ID: NCT06462508 Recruiting - Prostate Cancer Clinical Trials

Head-to-head Comparison of [18F]F-PSMA-N5 With [68Ga]Ga-PSMA-11 PET/CT in PCa Diagnosis, Recurrence, and Metastasis

Start date: April 20, 2024
Phase: Early Phase 1
Study type: Interventional

To prospectively evaluate the radiodrug biodistribution of a novel PET imaging agent [18F]F-PSMA-N5 in different organs of prostate cancer patients and its diagnostic efficacy in the diagnosis, recurrence and metastasis of prostate cancer, and to compare with [68Ga]Ga-PSMA-11.